Read More Pharma Industry News Immunomic Therapeutics begins ITI-1001 Phase 1 trial in glioblastoma Immunomic Therapeutics, Inc., a clinical-stage biotech company specializing in nucleic acid immunotherapy platforms, has dosed the first patient… byPallavi MadhirajuAugust 24, 2023